WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2006090376) PHARMACEUTICAL COMPOSITIONS OF THE ISOLATED D- ENANTIOMER OF THE QUINAZOLINONE DERIVATIVE HALOFUGINONE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2006/090376    International Application No.:    PCT/IL2006/000236
Publication Date: 31.08.2006 International Filing Date: 22.02.2006
IPC:
A61K 31/52 (2006.01), A01N 43/90 (2006.01)
Applicants: COLLGARD BIOPHARMACEUTICALS LTD. [IL/IL]; 15 Gonen Street, P.O. Box 7779, Kiryat Matalon, 49170 Petah Tikva (IL) (For All Designated States Except US).
EREZ, Mordechai [IL/IL]; (IL) (For US Only).
HALEVI, Karin [IL/IL]; (IL) (For US Only)
Inventors: EREZ, Mordechai; (IL).
HALEVI, Karin; (IL)
Agent: WEBB, Cynthia; WEBB & ASSOCIATES, P.O. Box 2189, 76121 Rehovot (IL)
Priority Data:
60/655,413 23.02.2005 US
Title (EN) PHARMACEUTICAL COMPOSITIONS OF THE ISOLATED D- ENANTIOMER OF THE QUINAZOLINONE DERIVATIVE HALOFUGINONE
(FR) COMPOSITION PHARMACEUTIQUE D'ENANTIOMERES D ISOLES DE DERIVES DE QUINAZOLINONE HALOFUGINONE
Abstract: front page image
(EN)The present invention relates to pharmaceutical compositions comprising as an active ingredient an isolated, chirally pure D-enantiomer of the quinazolinone derivative halofuginone having increased therapeutic activity and decreased side effects compared to the corresponding racemic mixtures, the composition being substantially free of the L-enantiomer and useful in the treatment of diseases and disorders associated with fibrotic conditions or cell proliferation.
(FR)La présente invention concerne une composition pharmaceutique comprenant comme principe actif un énantiomère D isolé de dérivé de quinazolinone halofuginone possédant une activité thérapeutique accrue et des effets secondaires moindres comparés aux mélanges racémiques correspondants, cette composition étant sensiblement exempte d'énantiomère L et convenant pour le traitement de maladies et de troubles associés aux états fibreux ou à la prolifération cellulaire.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)